School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
FEBS Open Bio. 2022 Dec;12(12):2191-2202. doi: 10.1002/2211-5463.13498. Epub 2022 Oct 28.
Nontypeable Haemophilus influenzae (NTHi) has emerged as a dominant mucosal pathogen causing acute otitis media (AOM) in children, acute sinusitis in children and adults, and acute exacerbations of chronic bronchitis in adults. Consequently, there is an urgent need to develop a vaccine to protect against NTHi infection. A multi-component vaccine will be desirable to avoid emergence of strains expressing modified proteins allowing vaccine escape. Protein D (PD), outer membrane protein (OMP) 26, and Protein 6 (P6) are leading protein vaccine candidates against NTHi. In pre-clinical research using mouse models, we found that recombinantly expressed PD, OMP26, and P6 induce robust antibody responses after vaccination as individual vaccines, but when PD and OMP26 were combined into a single vaccine formulation, PD antibody levels were significantly lower. We postulated that PD and OMP26 physiochemically interacted to mask PD antigenic epitopes resulting in the observed effect on antibody response. However, column chromatography and mass spectrometry analysis did not support our hypothesis. We postulated that the effect might be in vivo through the mechanism of protein vaccine immunologic antigenic competition. We found when PD and OMP26 were injected into the same leg or separate legs of mice, so that antigens were immunologically processed at the same or different regional lymph nodes, respectively, antibody levels to PD were significantly lower with same leg vaccination. Different leg vaccination produced PD antibody levels quantitatively similar to vaccination with PD alone. We conclude that mixing PD and OMP26 into a single vaccine formulation requires further formulation studies.
无乳链球菌(NTHi)已成为引起儿童急性中耳炎(AOM)、儿童和成人急性鼻窦炎以及成人慢性支气管炎急性加重的主要黏膜病原体。因此,迫切需要开发一种疫苗来预防 NTHi 感染。为了避免出现表达修饰蛋白从而逃避疫苗的菌株,多组分疫苗将是理想的选择。蛋白 D(PD)、外膜蛋白(OMP)26 和蛋白 6(P6)是针对 NTHi 的主要蛋白疫苗候选物。在使用小鼠模型的临床前研究中,我们发现重组表达的 PD、OMP26 和 P6 作为单独的疫苗接种后可诱导强烈的抗体反应,但当 PD 和 OMP26 组合成单一疫苗制剂时,PD 抗体水平显著降低。我们推测 PD 和 OMP26 在物理化学上相互作用,掩盖了 PD 抗原表位,导致观察到的抗体反应效应。然而,柱层析和质谱分析并不支持我们的假设。我们推测,这种效应可能是通过蛋白疫苗免疫抗原竞争的机制在体内发生的。我们发现,当 PD 和 OMP26 注入小鼠的同一条腿或不同的腿中,以便抗原分别在相同或不同的区域淋巴结进行免疫处理时,同一条腿接种 PD 和 OMP26 会导致 PD 抗体水平显著降低。不同腿接种产生的 PD 抗体水平与单独接种 PD 相似。我们得出结论,将 PD 和 OMP26 混合到单一疫苗制剂中需要进一步的制剂研究。